Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments
07 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/07/2977199/0/en/OPKO-Health-Reports-Third-Quarter-2024-Business-Highlights-and-Financial-Results.html
29 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/29/2971216/0/en/OPKO-Health-to-Report-Third-Quarter-2024-Financial-Results-on-November-7-2024.html
07 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/07/2958852/0/en/ModeX-Therapeutics-Secures-35-Million-BARDA-Supplement-to-Develop-COVID-Multispecific-Antibodies-and-16-Million-to-Initiate-Influenza-Program.html
25 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/25/2952944/0/en/Entera-Bio-and-OPKO-Health-Provide-Update-on-PK-PD-Results-of-Oral-Oxyntomodulin-GLP-1-Glucagon-Peptide-Tablet-Candidate-for-Obesity-and-Metabolic-Disorders.html
23 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/23/2951348/0/en/OPKO-Health-s-ModeX-Therapeutics-Appoints-Dr-Giovanni-Abbadessa-as-Chief-Medical-Officer-as-Pipeline-Advances-into-Clinical-Development.html
07 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/07/2926381/0/en/OPKO-Health-Reports-Second-Quarter-2024-Business-Highlights-and-Financial-Results.html
Details:
The funding will support the development of a novel multispecific antibody to SARS-CoV-2 from preclinical and influenza multispecifics with gene and/or protein delivery modalities.
Lead Product(s): MDX2202
Therapeutic Area: Infections and Infectious Diseases Brand Name: MDX2202
Study Phase: PreclinicalProduct Type: Large molecule
Sponsor: BARDA
Deal Size: $110.0 million Upfront Cash: Undisclosed
Deal Type: Funding October 07, 2024
Lead Product(s) : MDX2202
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : BARDA
Deal Size : $110.0 million
Deal Type : Funding
ModeX Secures $35M For COVID Antibodies, $16M For Influenza Program
Details : The funding will support the development of a novel multispecific antibody to SARS-CoV-2 from preclinical and influenza multispecifics with gene and/or protein delivery modalities.
Brand Name : MDX2202
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 07, 2024
Details:
OPKO retained a significant portion of Ngenla (somatrogon) through the agreement. It is an approved product, which is indicated for pediatric patients with growth hormone deficiency.
Lead Product(s): Somatrogon
Therapeutic Area: Endocrinology Brand Name: Ngenla
Study Phase: DiscoveryProduct Type: Peptide
Sponsor: HealthCare Royalty
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 17, 2024
Lead Product(s) : Somatrogon
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : HealthCare Royalty
Deal Size : $250.0 million
Deal Type : Agreement
OPKO and HealthCare Royalty Enter $250M Note Purchase Agreement Secured by NGENLA Payments
Details : OPKO retained a significant portion of Ngenla (somatrogon) through the agreement. It is an approved product, which is indicated for pediatric patients with growth hormone deficiency.
Brand Name : Ngenla
Molecule Type : Peptide
Upfront Cash : Undisclosed
July 17, 2024
Details:
Entera Bio & Opko Health are developing the first GLP-2 peptide tablet alternative for short bowel syndrome and mucosal inflammation disorders.
Lead Product(s): Undisclosed
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Peptide
Recipient: EnteraBio Ltd
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Recipient : EnteraBio Ltd
Deal Size : Not Applicable
Deal Type : Not Applicable
Entera Bio Reports Data for Oral GLP-2 Peptide Tablet in Short Bowel Syndrome
Details : Entera Bio & Opko Health are developing the first GLP-2 peptide tablet alternative for short bowel syndrome and mucosal inflammation disorders.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Not Applicable
March 20, 2024
Details:
The agreement aims to advance a platform and specific candidates addressing a range of viral infectious diseases and will enable research, development and clinical evaluation of potent multispecific antibodies, based on ModeX proprietary MSTAR technology.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Large molecule
Sponsor: BARDA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 28, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : BARDA
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims to advance a platform and specific candidates addressing a range of viral infectious diseases and will enable research, development and clinical evaluation of potent multispecific antibodies, based on ModeX proprietary MSTAR technology...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 28, 2023
Details:
NGENLA (somatrogon-ghla), a once-weekly, HGH analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. it's expected to become available for U.S. prescribing in August 2023.
Lead Product(s): Somatrogon-ghla
Therapeutic Area: Endocrinology Brand Name: Ngenla
Study Phase: ApprovedProduct Type: Large molecule
Recipient: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Lead Product(s) : Somatrogon-ghla
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Recipient : Pfizer Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves Pfizer’s NGENLA, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone D...
Details : NGENLA (somatrogon-ghla), a once-weekly, HGH analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. it's expected to become available for U.S. pres...
Brand Name : Ngenla
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 28, 2023
Details:
ModeX and Merck will jointly advance MDX-2201 to an IND application filing, after which Merck will be responsible for clinical and regulatory activities and product commercialization. MDX-2201 leverages ModeX’s innovative biologics platform to target multiple EBV proteins.
Lead Product(s): MDX-2201
Therapeutic Area: Infections and Infectious Diseases Brand Name: MDX-2201
Study Phase: IND EnablingProduct Type: Vaccine
Sponsor: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 08, 2023
Lead Product(s) : MDX-2201
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : ModeX and Merck will jointly advance MDX-2201 to an IND application filing, after which Merck will be responsible for clinical and regulatory activities and product commercialization. MDX-2201 leverages ModeX’s innovative biologics platform to target m...
Brand Name : MDX-2201
Molecule Type : Vaccine
Upfront Cash : Undisclosed
March 08, 2023
Details:
ModeX Therapeutics has developed highly flexible multi-specific antibody technology platforms with broad targeting and functional capabilities, simpler manufacturing and potentially better specificity and safety, providing significant differentiation from competing platforms.
Lead Product(s): Antibody
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Large molecule
Sponsor: OPKO Health
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition May 09, 2022
Lead Product(s) : Antibody
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : OPKO Health
Deal Size : $300.0 million
Deal Type : Acquisition
Details : ModeX Therapeutics has developed highly flexible multi-specific antibody technology platforms with broad targeting and functional capabilities, simpler manufacturing and potentially better specificity and safety, providing significant differentiation fro...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 09, 2022
Details:
The European Union marketing authorization of Ngenla (somatrogon) was supported by results from Phase 3 study which evaluated the safety and efficacy of once-weekly NGENLA compared to once-daily GENOTROPIN® (somatropin).
Lead Product(s): Somatrogon
Therapeutic Area: Endocrinology Brand Name: Ngenla
Study Phase: ApprovedProduct Type: Peptide
Recipient: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2022
Lead Product(s) : Somatrogon
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Recipient : Pfizer Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization ...
Details : The European Union marketing authorization of Ngenla (somatrogon) was supported by results from Phase 3 study which evaluated the safety and efficacy of once-weekly NGENLA compared to once-daily GENOTROPIN® (somatropin).
Brand Name : Ngenla
Molecule Type : Peptide
Upfront Cash : Not Applicable
February 15, 2022
Details:
RAYALDEE extended-release capsules are indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Lead Product(s): Calcifediol
Therapeutic Area: Endocrinology Brand Name: Rayaldee
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Vifor Fresenius Medical Care Renal Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2022
Lead Product(s) : Calcifediol
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Vifor Fresenius Medical Care Renal Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP
Details : RAYALDEE extended-release capsules are indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Brand Name : Rayaldee
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 03, 2022
Details:
Somatrogon is an investigational once-weekly long-acting recombinant human growth hormone for the treatment of growth hormone deficiency in pediatric patients. Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward.
Lead Product(s): Somatrogon
Therapeutic Area: Endocrinology Brand Name: PF-06836922
Study Phase: ApprovedProduct Type: Peptide
Recipient: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2022
Lead Product(s) : Somatrogon
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Recipient : Pfizer Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Somatrogon is an investigational once-weekly long-acting recombinant human growth hormone for the treatment of growth hormone deficiency in pediatric patients. Pfizer is evaluating the FDA’s comments and will work with the agency to determine an approp...
Brand Name : PF-06836922
Molecule Type : Peptide
Upfront Cash : Not Applicable
January 21, 2022
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?